Ryu Kariyawasam-Chavez, Content Associate

An investigational KRAS-targeted peptide vaccine generated durable immune responses and demonstrated early potential to intercept pancreatic cancer development in high-risk patients.

In a phase 4 study, 90.9% of patients receiving preoperative suzetrigine-based multimodal therapy avoided opioid rescue after aesthetic or reconstructive surgery.

Suzetrigine prescriptions approached 1 million in the first half of 2026 as reimbursed access expanded, signaling growing adoption of nonopioid acute pain treatment.

A cone snail venom–derived peptide selectively inhibited the norepinephrine transporter and reduced inflammatory pain behavior without sedation in mice.

The FDA approved once-daily centanafadine (Simtriyo), the first norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD in adults and children aged 6 years and older weighing at least 20 kg.

July 2026 brought advances in nonopioid drug development, opioid stewardship, procedural analgesia, cancer pain, pediatric medication safety, and understanding the genetic basis of fibromyalgia.

July 2026 brought major hematology advances in gene therapy, transplantation, targeted treatments, and bleeding disorder care, alongside notable clinical trial setbacks.

In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, discusses emerging bladder-preserving therapies for NMIBC, the limitations of single-arm trial data, the continued role of BCG, and the clinical and operational factors that should guide treatment selection.

A 19-protein plasma panel predicted whether and when presymptomatic carriers of ALS-associated pathogenic variants would develop clinically manifest disease more accurately than neurofilament light chain alone.

Angie Maynard, PharmD, MS, BCOP, discusses RCC immunotherapy guidelines, treatment selection, toxicity management, and pharmacists’ clinical role.

Subcutaneous isatuximab could compete with daratumumab in multiple myeloma by combining a hands-free, on-body delivery system with potential advantages in workflow, patient experience, and mechanisms of action.

Updated phase 1/2 findings showed that emavusertib-based therapy produced responses in both BTK inhibitor–naive and –treated patients with relapsed or refractory primary central nervous system (CNS) lymphoma.

Ravulizumab-cwvz did not significantly improve 26-week event-free survival in adults and adolescents with HSCT-associated thrombotic microangiopathy.

The FDA approved Tylenol with Naproxen, the first OTC fixed-dose combination of acetaminophen and naproxen sodium, for up to 12 hours of relief from minor aches and pains in patients 12 years and older.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, MCST, discusses where VER-01 could fit in chronic pain management and why advances in standardized cannabinoid therapies may represent a pivotal moment for the future of evidence-based cannabis-derived medicines.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, discusses what the phase 3 data reveal about VER-01's potential and explains how pharmacists could help integrate standardized cannabinoid therapies into evidence-based chronic pain management.

Cassandra Perkey, PharmD, BCOP, explains the operational, staffing, infrastructure, safety, and pharmacist-led requirements for successfully delivering CAR T-cell therapy in a community oncology setting.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, explains how VER-01 differs from dispensary cannabis products, emphasizing the importance of pharmaceutical standardization, consistent dosing, and rigorous clinical evaluation.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, discusses what sets VER-01 apart from previous cannabis-derived therapies, why it has generated significant interest in chronic pain research, and how its standardized pharmaceutical approach could shape the future of evidence-based pain management.

Cassandra Perkey, PharmD, BCOP, discusses how pharmacists support community CAR T-cell programs through SOP development, treatment planning, education, emergency preparedness, and lessons learned from treating the first patient.

In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, explains the staffing, infrastructure, hospital partnerships, and scheduling strategies needed to safely deliver outpatient CAR T-cell therapy in a community oncology setting.

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, RPh, MS, MCST, discusses how VER-01 could reshape the role of cannabis-derived medicines in chronic pain care, the evolving role of pharmacists, and why pharmaceutical cannabinoids and whole-plant cannabis should be viewed as complementary therapeutic options rather than competitors.

In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, discussed the patient selection, standardized workflows, toxicity management, payer coordination, and caregiver education needed to safely move bispecific step-up dosing into the outpatient setting.

In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, outlines the essential teams, SOPs, financial planning, and safety protocols community oncology practices need to launch outpatient CAR T-cell therapy successfully.

In an interview with Pharmacy Times, Cherise Steib, PharmD, HDDP, discussed patient selection, caregiver requirements, cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and the American Oncology Network’s approach to building an outpatient bispecific therapy program.

In an interview with Pharmacy Times, Steib explains how structured monitoring, patient education, emergency protocols, and pharmacist involvement support the safe delivery of outpatient bispecific therapy.

Cherise Steib, PharmD, HDDP, discusses how bispecific therapies expand treatment options and the factors that determine whether patients are appropriate candidates for outpatient administration.

Some commonly used treatments for chronic low back pain may offer limited benefit while increasing risks, underscoring the need for pharmacists to support evidence-based, patient-centered care.

In an interview with Pharmacy Times, Maksour explained how payer restrictions on prophylactic tocilizumab and the need for intensive patient and caregiver education can influence the safety and feasibility of outpatient bispecific therapy.

Outpatient BiTE therapy for multiple myeloma may be safely supported in community oncology settings through careful patient selection, pharmacist-led coordination, home monitoring, caregiver education, and standardized protocols for managing CRS and ICANS.